2014 Program Schedule

TUESDAY, NOVEMBER 4
Early Bird Registration   2-9 PM

 

WEDNESDAY, NOVEMBER 5

 

8:00        WELCOME

Edward Ambinder, MD, Steven Burakoff, MD, Janice Gabrilove, MD

Breakfast Bar 

MORNING SESSION
HEMATOLOGIC MALIGNANCIES

Moderators: Janice Gabrilove, MD, Kanti Rai, MD

CLL

8:15        P13K INHIBITION (IDELALISIB) IN CLL

Susan O'Brien, MD

8:30        BTK-INHIBITOR DRUGS AND NEWER DRUGS ON THE HORIZON FOR CLL

Jacqueline Barrientos, MD

8:45        AURANOFIN AS A POTENT AGENT IN CLL

Kapil Bhalla, MD

AML & MYELOID MALIGNANCIES

9:00        CHANGING TREATMENT IN AML

Gail Roboz, MD

9:15         THE EVOLVING LANDSCAPE OF MUTATIONS IN MYELOID MALIGNANCIES

Francine Garrett-Bakelman, MD                

LYMPHOMAS

9:30     DIFFUSE LARGE B-CELL LYMPHOMA AND MANTLE CELL LYMPHOMA: RECENT ADVANCES

Andre Goy, MD

9:45       VACCINE STRATEGIES IN FOLLICULAR LYMPHOMA

Joshua Brody, MD

10:00     Coffee Break

MYELOPROLIFERATIVE NEOPLASMS

10:30      NEW DIRECTIONS IN THE TREATMENT OF MPN PATIENTS

Ronald Hoffman, MD

ALL

10:45      ISSUES IN ADOLESCENT AND YOUNG ADULT (AYA) ONCOLOGY

Peter Coccia, MD

MYELOMA & WALDENSTROM'S DISEASE

11:OO      NEW DRUGS IN MULTIPLE MYELOMA

Sundar Jagannath, MD

11:15      IBRUTINIB IN WALDENSTROM’S MACROGLOBULINEMIA        

Steven Treon, MD

11:30      OncEd and Commentary

Janice Gabrilove, MD

Lunch Station          

12:00 FEATURED PRESENTATION

          To Be Announced

 

AFTERNOON SESSION

KEYNOTE ADDRESS

1:00           PAST AS PRELUDE: FURTHER DILEMMAS IN HORMONAL TREATMENT OF EARLY BREAST CANCER

Norman Wolmark, MD

 

1:20          THE HISTORY OF MEDICAL ONCOLOGY FROM EARLY DAYS

TO THE CREATION OF THE SUBSPECIALTY

Pierre R. Band, MD, James F. Holland, MD

 

GI CANCERS

Moderators: Jordan Berlin, MD, Howard Hochster, MD, Randall Holcombe, MD

1:50        ROLE OF TCGA IN GASTRIC CANCER

Adam Bass, MD              

CRC

2:05       STOOL-DNA IS EFFECTIVE IN COLON CANCER SCREENING:

              NEW FINDINGS

Steven Itzkowitz, MD

2:20        CRC: DO WE TREAT RAS SUBSETS DIFFERENTLY?

Alan Venook, MD

2:35        COLORECTAL CANCER: NEW DIRECTIONS IN CHEMOPREVENTION

Jason Zell, MD

2:50        REDUCING RISK OF COLON CANCER RECURRENCE WITH EXERCISE

Christopher M. Booth, MD          

3:05        Coffee Break

PANCREATIC CANCER

3:35       DIVERGENT VIEWS: FOLFIRINOX VS GEMCITABINE-ABRAXANE

               IN PANCREATIC CANCER

Jordan Berlin, MD, Howard Hochster, MD

3:50       THE NAPOLI-1 TRIAL IN PANCREATIC CANCER

Wen Wee Ma, MD

4:05        MEK INHIBITORS IN BILIARY CANCER

Anthony El-Khoueiry, MD

4:20        OPTIMIZING THE IMMUNE SYSTEM

Dung Thi Le, MD

4:35        MOLECULAR DIAGNOSIS: CIRCULATING DNA IN PLASMA

Luis Diaz, MD

4:50          OncEd and Commentary

Jordan Berlin, MD

 

PEDIATRIC ONCOLOGY

Marquis Ballroom, 9th Floor

Chair: Birte Wistinghausen, MD

1:30        PEDIATRIC CANCER GENOME

Michael Dyer, MD

1:50        PEDIATRIC PRECLINICAL TESTING PROGRAM

Richard Gorlick, MD

2:10        NOVEL THERAPIES IN NEUROFIBROMATOSIS TYPE 2

Matthias Karajannis, MD

2:30        THE EPIDEMIOLOGY OF SECOND MALIGNANCIES

Robert Goldsby, MD

2:50        Coffee Break

3:10        NEW THERAPIES FOR ALL

Elizabeth Raetz, MD

3:30        FUTURE OF CELLULAR THERAPIES

Mitchell Cairo, MD

3:50         MABs AND TKIs IN THE TREATMENT OF ANAPLASTIC LARGE CELL LYMPHOMA

Eric Lowe, MD

4:10        OncEd and Commentary

 

 

THURSDAY, NOVEMBER 6

 

Breakfast Bar

MORNING SESSION
GYNECOLOGICAL CANCERS

Moderators: Franco Muggia, MD, Tamar Safra, MD

8:00        UPDATE ON CHEMOTHERAPY FOR ENDOMETRIAL CANCER

Franco M. Muggia, MD

8:15        ANTI-ANGIOGENESIS IN OVARIAN CANCER TREATMENT: WHICH DRUGS AND WHEN?

William McGuire, MD

8:30        THE LATEST ON PARP INHIBITOR AND STRATEGIES IN BRCA CARRIERS

Tamar Safra, MD

8:45        ENDPOINTS FOR DRUG APPROVAL IN OVARIAN CANCER

Jason Wright, MD

9:00        TARGETING HER2 IN GYNECOLOGIC CANCERS

Allessandro Santin, MD

9:15        IDENTIFYING NEW TARGETS: PATIENT DERIVED TUMORS IN OVARIAN AND UTERINE CANCERS

Michael J. Birrer, MD

9:30        INCLUDING GYN CANCERS IN BASKET TRIALS

David Hyman, MD

9:45        OncEd and Commentary

Franco M. Muggia, MD

10:00       Coffee Break

HEAD AND NECK CANCERS

Moderator: Krzysztof J. Misiukiewicz, MD

10:30      NEW FINDINGS IN MANAGEMENT OF THYROID CANCERS

Marcia Brose, MD

10:45     REDUCED DOSAGE TREATMENT IN HEAD AND NECK CANCER

Barbara Burtness, MD

11:00      IMMUNOTHERAPUTIC APPROACHES: HEAD AND NECK CANCERS

Andrew Sikora, MD

11:10  OncEd

Marcia Brose, MD

CNS MALIGNANCIES

11:25      BEVACIZUMAB IN GLIOBLASTOMA: PROs CONs AND OTHERWISE

Howard Fine, MD

11:40      TREATING BRAIN TUMORS: NEW DEVELOPMENTS?

Deborah Gruber, MD

11:55  OncEd

Howard Fine, MD

Lunch Station

12:00  FEATURED PRESENTATION

          To Be Announced

1:00 EZRA M. GREENSPAN MEMORIAL LECTURE

PI3K/TOR PATHWAY INHIBITORS IN THE TREATMENT

OF BREAST CANCER

Carlos L. Arteaga, MD

AFTERNOON SESSION

BREAST CANCER

Moderators: Harold Burstein, MD, Larry Norton, MD, Seymour Cohen, MD

1:25        BREAST CANCER AND ITS MICROENVIRONMENT: NEW CONCEPTS

Larry Norton, MD

1:40        CHECKPOINT INHIBITION IN BREAST CANCER: ANTI-CTLA-4 AND ANTI-PD-1 STUDY

Heather McArthur, MD

1:55        PALBOCICLIB WITH ADJUVANT ENDOCRINE THERAPY FOR HORMONE RECEPTOR POSITIVE INVASIVE BREAST CANCER

Erica L. Mayer, MD 

2:10    CDK4/5 INHIBITORS: PHASE II AND PHASE I STUDIES

Sara Tolaney, MD

2:25        ER MUTATIONS AND RESISTANCE: NEW SEQUENCING DATA

Rinath Jeselsohn, M.D.     

2:40        SERDS: SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND EMERGING DATA

Maura Dickler, MD

2:55        TRIPLE-NEGATIVE BREAST CANCER

Lisa Carey, MD

3:10        Coffee Break

3:40        BREAST CANCER AND OBESITY

Clifford Hudis, MD

3:55        ADJUVANT THERAPY FOR HER2+ BREAST CANCER

Jose Baselga, MD

4:10        NEW AGENTS FOR ADVANCED HER2+ BREAST CANCER

Kimberly Blackwell, MD

4:25        CLINICAL TRIALS WITH TRASTUZUMAB BIOSIMILARS

Franco Esteva, MD

4:40        OncEd and Commentary

Harold Burstein, MD

 

FRIDAY, NOVEMBER 7

 

Breakfast Bar

MORNING SESSION

GENITOURINARY ONCOLOGY

Moderators: William Oh, MD, Anna Ferrari, MD

8:00     IMPROVING CLINICAL TRIAL ACCRUAL IN GU CANCERS: CROWDSOURCING AND IT

Matthew Galsky, MD

Prostate Cancer

8:15        IMMUNOTHERAPY IN PROSTATE CANCER: A NEW ERA? 

James Gulley, MD

8:30        THE EVOLVING ROLE OF CHEMOTHERAPY FOR HORMONE SENSITIVE PROSTATE CANCER 

Chris Sweeney, MD                                               

8:45        TARGETING NEUROENDOCRINE DIFFERENTIATION

Himisha Beltran, MD 

9:00        WHAT’S NEXT FOR TARGETING THE ANDROGEN PATHWAY IN PROSTATE CANCER?  

Nima Sharifi, MD

9:15        OPTIMIZING THE SEQUENCE OF NEW TREATMENTS FOR CRPC

William Oh, MD

Renal Cancer

9:30         GENETICS OF KIDNEY CANCER: PAVING THE WAY FOR THE NEXT GENERATION OF THERAPIES

James Brugarolas, MD      

9:45        LIMITING TREATMENT RELATED MORBIDITY IN RCC: OBSERVATION AND INTERMITTENT RX

Brian Rini, MD

10:00        IMMUNOTHERAPY IN RCC: BACK TO THE FUTURE

Benjamin Gartrell, MD

Bladder Cancer

10:15       NEW DRUGS FOR METASTATIC BLADDER CANCER 

Matthew Milowsky, MD

10:30      Coffee Break

LUNG CANCER

Moderators: Chandra P. Belani, MD, Roman Perez-Soler, MD

10:45      TARGETING PD-1 AND PD-L1 IN NSCLC

Chandra P. Belani, MD

11:05      PRACTICAL APPLICATION OF GENOMIC TOOLS IN THE MANAGEMENT OF NON-SMALL CELL LUNG CANCER

Roman Perez-Soler, MD

11:25      SELECT NOVEL AGENTS IN LUNG CANCER

Panel: Chandra Belani, MD, Shirish Gadgeel, MD, Suresh Ramalingam, MD, Christine Lovly, MD, David Spigel, MD, Nasser Altorki, MD, Corey Langer, MD

AZD 9291, CO 1686, AT-13387, Ceritinib, Onartuzumab. Erlotinib: Radiant Trial, Afatinib                     

11:50 OncEd

Chandra P. Belani, MD

 

Lunch Station

 

12:00 FEATURED  PRESENTATION

APPLE-IZATION: A CREATIVE TRANSFORMATION OF

HEALTH INFORMATION TECHNOLOGY

Clinical Practice and Research in Cancer

Edward Ambinder, MD and Panel

 

AFTERNOON SESSION

DIVERSE TOPICS

Moderator: Edward Ambinder, MD

1:15    CANCER TREATMENTS CHANGE, BUT NOT PATIENTS’ EMOTIONS: THE PSYCHOLOGICAL ISSUES REMAIN THE SAME

Jimmie C. Holland, MD

1:35   DRUG CONJUGATES BIND COVALENTLY TO ALBUMIN: A NEW APPROACH

Sant Chawla, MD

1:50   NCI CTEP OVERVIEW

John Wright, MD

2:05   MULTICELLULARITY EFFECTS ON CANCER METABOLISM

Craig Thompson, MD  

2:20  REPURPOSING OF METFORMIN FOR CANCER PREVENTION AND TREATMENT: GETTING BACK TO BASICS

Benjamin Levy, MD

2:35  SARCOMA TRIALS 2014: AN ALPHABET SOUP?

Robert Maki, MD

2:50 ADOPTIVE T CELL THERAPY: BUILDING ON SUCCESS

Christopher Klebanoff, MD

 

Snacktime MeetUp

3:05  Attendees and Faculty

 

Attendees are not required to sign in for any individual activities.

 

 
  

EMERGING DEVELOPMENTS

  Advances In Immuno-Oncology Based Therapies
  Albumin-Binding Drug Conjugates
  DNA-Based Diagnostic Systems
  Genetic Bridges To Selective Therapies
  Gene Sequencing
  Harnessing The Immune System
  Metabolic Activity In Solid Tumors
  Molecular Diagnostic Modalities
  Mutations and Treatment Change
  New Generation Delivery Systems
  Patient-Derived Tumor Cells
  Targeting Cancer-Killer Cells
  Tracking Tumor Markers
  Twenty First Century Vanguards

HIGHLIGHTS OF MULTI-SPECIALTY SESSIONS

  HEMATOLOGY
  AML, ALL, CLL, Lymphomas, Myelodysplastic Diseases, Novel Agents and Targets, Vaccines, Pediatric Cancers in Adulthood and Differential Mutations
   
  GI CANCERS
  CRC, Pancreatic, Gastic, Biliary
  21ST Century Screening and Therapy
  DNA-Based Diagnosis
  Reducing Recurrence-Risk with Exercise
   
  GYNECOLOGICAL CANCERS
  Patient-Derived Tumor Cells
  Ovarian Trial Endpoints
  PARP Inhibitors
  Endometrial Therapy Updated
  The BASKET Trials
  BRCA Carriers
   
  BREAST CANCER
  The MicroEnvironment
  ER Mutations and Resistance
  Adjuvant Endocrine Therapy
  SERDS: Estrogen Receptor Degraders
  Immune Checkpoint Blockaders
   
  GENITOURINARY: Prostate, Renal, Bladder
  Hormone Sensitivity
  Neuroendocrine Differentiation
  Targeting the Androgen Pathway
  Genetic-Related Treatment Concepts
  Limiting Treatment-Related Morbidity
  New Agents in Metastatic Disease
   
  THYROID CANCER 
  New Clinical Trial Data
   
  LUNG CANCER 
  Genomic Tools
  Activating New Targets
  Novel AntiTumor Active Agents
   
  SARCOMAS 
  Clinical Trials Results
  Albumin as a Targeting Agent
   
  IMMUNOLOGY 
  Natural Tumor-Killer Cells
   
  PEDIATRIC ONCOLOGY 
  Advances in Therapy of Children and Young Adults
   
  CNS 
  Treating Glioblastoma

Register Now

 

This program has been developed in collaboration with the Tisch Cancer Institute of the Icahn School of Medicine at Mount Sinai.